STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology

Cidara Therapeutics Reacquires Flu Program and Secures $240M in Private Placement

byLuca Blaumann
May 16, 2024
in Biotechnology, Micro-Cap
Reading Time: 2 mins read
Share on TwitterShare on LinkedIn

Strategic Shift Allows Cidara Therapeutics to Focus on Cloudbreak Platform for Universal Influenza Protection

Cidara Therapeutics, Inc. (Nasdaq: CDTX) reported a net loss of $10.3 million for the quarter, a stark contrast to the $3.0 million net income in the same period last year, reflecting strategic shifts and increased focus on key projects.

Key among these updates is the reacquisition of exclusive global development and commercial rights to CD388 from Janssen Pharmaceuticals. CD388, a once-per-season universal preventative for influenza A and B, is slated for a Phase 2b clinical trial during the upcoming Northern Hemisphere influenza season. This strategic move allows Cidara to concentrate on its Cloudbreak DFC platform, which promises broader protection beyond traditional flu vaccines.

The company also announced a successful $240.0 million private placement, led by RA Capital Management with participation from Bain Capital Life Sciences, Biotech Value Fund, and Canaan Partners. The funding, of which $85.0 million was used for the reacquisition of CD388, will support further development of this promising flu preventative. Jeffrey Stein, Ph.D., Cidara’s CEO, emphasized the potential of CD388 to provide universal protection, even in the absence of a robust immune system, without the need for seasonal strain predictions.

In another strategic move, Cidara divested its rezafungin program to Mundipharma, expecting approximately $128.0 million in cost savings over the patent life of rezafungin. This divestiture aligns with Cidara’s sharpened focus on its DFC platform.

Corporate changes also included the appointment of new board members Laura Tadvalkar, Ph.D., Ryan Spencer, and James Merson, Ph.D., following the private placement.

Despite a drop in revenue to $8.5 million from $26.1 million in the same quarter last year, Cidara’s strategic realignment and robust funding position the company for significant advancements in combating serious infectious diseases. The upcoming trials for CD388 are highly anticipated, as they represent a critical step toward potentially transforming flu prevention and setting a new standard of care.

Clickhereto read the original press release.

You might like this article:Netflix Enters Live Sports: Strikes Deal to Stream NFL Games on Christmas Day

Tags: cidara
Previous Post

Uber Unveils Innovative Features at Go-Get Showcase to Enhance User Experience

Next Post

Oncocyte Announces Bio-Rad Partnership and Raises $15.8M to Accelerate Transplant Diagnostic Launch

Related Posts

Serina Therapeutics Advances Parkinson’s Program After Key FDA Green Light

byLuca Blaumann
January 29, 2026
0

IND clearance positions SER-252 for clinical progress in advanced Parkinson’s disease treatment Serina Therapeutics (SER) announced a significant regulatory milestone...

investing

GITS Secures Global Rights to ATEEZ Theme Song for The Legend of MegaRace

byLiliana Vida
January 27, 2026
0

Deal strengthens IP ownership strategy and launches worldwide promotional campaign tied to the animated franchise Global Interactive Technologies (GITS), a...

scientist

AI Is Already Transforming Drug Development—Just Not Where Investors Expected

byLuca Blaumann
January 26, 2026
0

While “AI-discovered” breakthrough medicines are still emerging, pharma is using AI today to cut costs, speed trials, and reduce regulatory...

Next Post

Oncocyte Announces Bio-Rad Partnership and Raises $15.8M to Accelerate Transplant Diagnostic Launch

Latest News

Bitcoin Slides After Treasury Pushback Signals No Government Backstop

Advanced Micro Devices Beats Earnings, but Shares Slide as AI Expectations Stay Sky-High

Intel Signals GPU Ambitions in Bid to Reclaim Data Center Relevance

Earnings Season Hits a Crucial Stretch as Tech Strength Meets Consumer Caution

Bitcoin Slips as Traders Rotate Toward Metals and Defensive Bets

Based on Your Interest

Artificial Intelligence

KULR Technology: The Market Trades Bitcoin — I’m Watching the Battery Business

February 3, 2026
Artificial Intelligence

Advanced Micro Devices Earnings Poised to Test the AI Trade’s Staying Power

February 3, 2026
Artificial Intelligence

Palantir Technologies Braces for High-Stakes Earnings as AI Momentum Collides With Valuation Debate

February 2, 2026

Recommended

Biotechnology

Serina Therapeutics Advances Parkinson’s Program After Key FDA Green Light

January 29, 2026
Large-Cap

Nike’s Path Back to $100: Why the Bull Case Is Regaining Momentum

January 29, 2026
Aerospace & Defense

Earnings Season Hits Full Throttle as Big Tech and AI Set the Pace for 2026

January 28, 2026
Beverages

Starbucks Posts First U.S. Same-Store Sales Growth in Two Years

January 28, 2026
Ground Transportation

Robotaxi Prices Are Falling—and the Gap With Uber and Lyft Is Closing

January 27, 2026
Stoxpo

Follow us on social media:

Highlights

  • Bitcoin Slides After Treasury Pushback Signals No Government Backstop
  • Advanced Micro Devices Beats Earnings, but Shares Slide as AI Expectations Stay Sky-High
  • Intel Signals GPU Ambitions in Bid to Reclaim Data Center Relevance
  • Earnings Season Hits a Crucial Stretch as Tech Strength Meets Consumer Caution
  • Bitcoin Slips as Traders Rotate Toward Metals and Defensive Bets

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Bitcoin Slides After Treasury Pushback Signals No Government Backstop

February 4, 2026
investing

Advanced Micro Devices Beats Earnings, but Shares Slide as AI Expectations Stay Sky-High

February 4, 2026
investing

Intel Signals GPU Ambitions in Bid to Reclaim Data Center Relevance

February 3, 2026
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.